Tweets
Baker et al. TNFi vs triple therapy by BMI. 907 patients from TEAR/RACAT. Those under/normal weight have a better response to TNFi, overweight/obese respond equally to both. Abstr#2541 #ACR23 @RheumNow https://t.co/SROD3esMCD https://t.co/ni3I8tD7wI
Richard Conway ( View Tweet )
2 years 3 months ago
Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux?
Antibody titres better when not getting regular ritux around boosters
Maybe boosters 9mo (or so) gap after ritux helps immunogenicity
@TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx
David Liew @drdavidliew ( View Tweet )
2 years 3 months ago
The Lupus APOL1 Story
Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4
Dr. John Cush @RheumNow ( View Tweet )
2 years 3 months ago
ROMO vs DEN.
Romosozumab was superior to denosumab
(ROMO +7.3±4.5%; p< 0.001) and (DEN +2.3±3.1%; p< 0.001) in raising the spine BMD but not in hip at month 12 in chronic GC users with high fracture risk
Mok C Abst#242 #ACR23 @RheumNow https://t.co/q2OKD6C2Me
Dr. Antoni Chan ( View Tweet )
2 years 3 months ago
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Janet Pope ( View Tweet )
2 years 3 months ago
Wouldn’t it be great to be able to predict which women with RA would improve during pregnancy, & which would worsen? We’d be able to adjust DMARDs accordingly.
Gene expression signatures might tell us more - one key cluster here was 21x predictive.
#ACR23 ABST2481 @RheumNow https://t.co/OiDV5sUiYC
David Liew @drdavidliew ( View Tweet )
2 years 3 months ago
#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE
Md Yuzaiful Md Yusof ( View Tweet )
2 years 3 months ago
During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations.
⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM
➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
HCQ and risk of retinopathy 👁️
DoD database HCQ 44000+ females & 10000+ males
Risk retinopathy HR 1.5
Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7
No adjustment on HCQ dose
@RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45
Aurelie Najm ( View Tweet )
2 years 3 months ago
@md_chawla @RheumNow https://t.co/PVxox5t8ZH
Links:
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
@md_chawla @RheumNow https://t.co/qSdT7by1Vh
Links:
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 3 months ago
Erosive hand #OA may be more painful than treated #RA patients. The burden of OA is often not alked about, and this study highlights it! @RheumNow #ACR23 https://t.co/jLbvtMmgE0
Bella Mehta @bella_mehta ( View Tweet )
2 years 3 months ago
